Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MD DISPENSING BILL IS LIKELY TO BE DEFERRED FOR MEASURES WITH MORE SENATE INTEREST

Executive Summary

MD DISPENSING BILL IS LIKELY TO BE DEFERRED FOR MEASURES WITH MORE SENATE INTEREST, House Commerce/Health Subcommittee Counsel William Corr indicated at a June 24 session of the midyear meeting of the National Association of Pharmaceutical Manufacturers. Although the legislation (HR 2168) has passed the Health Subcommittee and the full Energy & Commerce Committee, Corr expressed doubts about the bill's future. "It was very controversial in our committee," he noted. "It did pass the committee, [but] I think it probably has seen its end." It is still unclear whether the bill will be considered on the House floor, Corr maintained. Further, the bill has yet to be introduced in the Senate. [The Senate International Trade Subcommittee, chaired by Sen. Matsunaga (D-Hawaii) declined to address MD dispensing during its recent hearings on drug diversion legislation.] "There's a lot [of legislative activity] we've been working on these days, so it's yet to be seen as to whether that legislation gets to the House floor," he said.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel